Dr. Allan Goldstein

During the meeting Dr. Allan Goldstein, the Company's Chairman and Chief Scientific Advisor presented the latest research data related to Thymosin beta 4 (TB4), the basis of the Company's wound healing technology platform.He also explained how TB4 accelerated wound healing in animals and discussed how its mechanism of action could be applicable across a spectrum of clinical indications, including tissue repair in the eye and surrounding tissues.